McAdam LLC’s Jazz Pharmaceuticals JAZZ Stock Holding History

McAdam LLC’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-62	Closed	-$10K	–	343
2018 Q3	$10K	Hold	62	–	–	﹤0.01%	340
2018 Q2	$11K	Hold	62	–	–	﹤0.01%	320
2018 Q1	$9K	Buy	+62	New	+$9.1K	﹤0.01%	340

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

McAdam LLC's JAZZ Position: Q4 2018 in Review

McAdam LLC sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 62 shares — an estimated $10K sold.

McAdam LLC first reported a position in JAZZ in Q1 2018 and held it in 3 quarters. The position peaked at $11K in Q2 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

McAdam LLC reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 62 Jazz Pharmaceuticals shares in Q4 2018, an estimated $10K.
McAdam LLC first reported a position in Jazz Pharmaceuticals in Q1 2018 and held it in 3 quarters.
McAdam LLC's Jazz Pharmaceuticals position peaked at $11K in Q2 2018.
417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.